SuperworthBIO-TECHNE EPS TECH
Diluted earnings per share by quarter and over the last twelve months, from 2009.
- Last 12 months, to Jun 30, 2026
- $1.15
- Latest quarter, Q4 FY26
- $0.35
- Fiscal year 2026
- $1.15
- +150% on the year before
BIO-TECHNE's earnings per share was $1.15 over the twelve months to Jun 30, 2026, up 150% on a year earlier.
In its latest quarter, Q4 FY26, it was $0.35.
Over the five fiscal years to FY2026 it grew 6% a year on average.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2026 | $1.15 | +150% |
| FY2025 | $0.46 | −56% |
| FY2024 | $1.04 | −41% |
| FY2023 | $1.76 | +6% |
| FY2022 | $1.66 | +92% |
| FY2021 | $0.86 | −40% |
| FY2020 | $1.45 | +134% |
| FY2019 | $0.62 | −25% |
| FY2018 | $0.83 | +63% |
| FY2017 | $0.51 | −28% |
| FY2016 | $0.70 | −3% |
| FY2015 | $0.72 | −3% |
| FY2014 | $0.75 | −2% |
| FY2013 | $0.77 | +1% |
| FY2012 | $0.76 | +1% |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q4 FY26 | $0.35 | n/a | $1.15 | |
| Q3 FY26 | $0.32 | +129% | $0.69 | |
| Q2 FY26 | $0.24 | +9% | $0.51 | |
| Q1 FY26 | $0.24 | +14% | $0.49 | |
| Q4 FY25 | −$0.11 | −144% | $0.46 | |
| Q3 FY25 | $0.14 | −55% | $0.82 | |
| Q2 FY25 | $0.22 | +29% | $0.99 | |
| Q1 FY25 | $0.21 | −32% | $0.94 | |
| Q4 FY24 | $0.25 | −47% | $1.04 | |
| Q3 FY24 | $0.31 | −28% | $1.26 | |
| Q2 FY24 | $0.17 | −45% | $1.38 | |
| Q1 FY24 | $0.31 | −44% | $1.52 |
Against its peers
Companies in Biotechnology nearest BIO-TECHNE's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| TECHBIO-TECHNE | $1.15 | +150% a year |
| RGENRepligen | $0.73 | |
| KRYSKrystal Biotech | $7.98 | +62% a year |
| HALOHalozyme Therapeutics | $3.35 | −23% a year |
| NBIXNeurocrine Biosciences | $6.82 | +102% a year |
| EXELExelixis | $3.18 | +53% a year |
| INCYIncyte | $7.85 | +78% a year |
| UTHRUnited Therapeutics | $27.95 | +9% a year |
| ALNYAlnylam Pharmaceuticals | $5.93 | |
| ONCBeOne Medicines | $0.43 | |
| ADMAAdma Biologics | $0.70 | −18% a year |
| Peer median | $4.64 |
Where BIO-TECHNE ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on BIO-TECHNE
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.